Evidence map›Paper›PMID 39018498›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2024

The potential and pitfalls of using a large language model such as ChatGPT, GPT-4, or LLaMA as a clinical assistant.

Jingqing Zhang, Kai Sun, Akshay Jagadeesh, Parastoo Falakaflaki, Elena Kayayan, Guanyu Tao, Mahta Haghighat Ghahfarokhi, Deepa Gupta, Ashok Gupta, Vibhor Gupta and 1 more

Abstract read
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Large Language Models and Primary Care: A Scoping Review.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingqing ZhangPangaea Data Limited, London, SE1 7LY, United Kingdom.ORCID 0000-0002-8822-736X
Kai SunPangaea Data Limited, London, SE1 7LY, United Kingdom.
Akshay JagadeeshPangaea Data Limited, London, SE1 7LY, United Kingdom.
Parastoo FalakaflakiPangaea Data Limited, London, SE1 7LY, United Kingdom.
Elena KayayanPangaea Data Limited, London, SE1 7LY, United Kingdom.
Guanyu TaoPangaea Data Limited, London, SE1 7LY, United Kingdom.
Mahta Haghighat GhahfarokhiPangaea Data Limited, London, SE1 7LY, United Kingdom.
Deepa GuptaPangaea Data Limited, London, SE1 7LY, United Kingdom.
Ashok GuptaPangaea Data Limited, London, SE1 7LY, United Kingdom.
Vibhor GuptaPangaea Data Limited, London, SE1 7LY, United Kingdom.
Yike GuoPangaea Data Limited, London, SE1 7LY, United Kingdom.

Funding

Pangaea Data Limited
6 · The paper itself

Abstract

objectivesThis study aims to evaluate the utility of large language models (LLMs) in healthcare, focusing on their applications in enhancing patient care through improved diagnostic, decision-making processes, and as ancillary tools for healthcare professionals. MATERIALS AND

methodsWe evaluated ChatGPT, GPT-4, and LLaMA in identifying patients with specific diseases using gold-labeled Electronic Health Records (EHRs) from the MIMIC-III database, covering three prevalent diseases-Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Disease (CKD)-along with the rare condition, Primary Biliary Cirrhosis (PBC), and the hard-to-diagnose condition Cancer Cachexia.

resultsIn patient identification, GPT-4 had near similar or better performance compared to the corresponding disease-specific Machine Learning models (F1-score ≥ 85%) on COPD, CKD, and PBC. GPT-4 excelled in the PBC use case, achieving a 4.23% higher F1-score compared to disease-specific "Traditional Machine Learning" models. ChatGPT and LLaMA3 demonstrated lower performance than GPT-4 across all diseases and almost all metrics. Few-shot prompts also help ChatGPT, GPT-4, and LLaMA3 achieve higher precision and specificity but lower sensitivity and Negative Predictive Value. DISCUSSION: The study highlights the potential and limitations of LLMs in healthcare. Issues with errors, explanatory limitations and ethical concerns like data privacy and model transparency suggest that these models would be supplementary tools in clinical settings. Future studies should improve training datasets and model designs for LLMs to gain better utility in healthcare.

conclusionThe study shows that LLMs have the potential to assist clinicians for tasks such as patient identification but false positives and false negatives must be mitigated before LLMs are adequate for real-world clinical assistance.

Indexed as

Electronic Health RecordsPulmonary Disease, Chronic ObstructiveHumansLiver Cirrhosis, BiliaryMachine LearningNatural Language ProcessingRenal Insufficiency, ChronicChatGPThealthcare artificial intelligencelarge language modelspatient identification

Identifiers

PMID39018498
PMCPMC11339517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.